TRVI — Trevi Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1563880 ·
Last close
$13.51
Market Cap
$1.93B
52W High
$20.22
52W Low
$9.82
ADV30
2,211,372
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -24,486,000 | -21,452,000 | 310,812,000 | 27,849,000 | 8,056,000 |
| Jun 2026 | 0 | — | -20,509,000 | -17,797,000 | 330,518,000 | 54,302,000 | 9,012,000 |
| Mar 2026 | 0 | — | -14,912,000 | -13,192,000 | 179,606,000 | 19,412,000 | 7,479,000 |
| Dec 2025 | 0 | — | -10,220,000 | -8,316,000 | 193,439,000 | 18,914,000 | 10,195,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-61,436,000
Investing CF
$-132,859,000
Financing CF
$165,275,000
CapEx
$-251,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.39
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-382,245,000
Inventory
—
Receivables
—
ST Investments
$271,559,000
EBIT TTM
$-68,239,000
Pretax Income TTM
$-60,831,000
Interest Exp TTM
$0
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -49,328,000 | -42,759,000 | 193,439,000 | 10,195,000 | 183,244,000 | -42,089,000 |
| Dec 2024 | 0 | -51,524,000 | -47,911,000 | 110,900,000 | 11,256,000 | 99,644,000 | -38,256,000 |
| Dec 2023 | 0 | -33,923,000 | -29,065,000 | 89,403,000 | 6,856,000 | 82,547,000 | -31,710,000 |
| Dec 2022 | 0 | -29,907,000 | -29,152,000 | 123,015,000 | 15,556,000 | 107,459,000 | -28,175,000 |
TTM Snapshot
Revenues TTM
$8,396,000
NetIncome TTM
$-51,107,000
OpCashFlow TTM
—
Assets (Latest)
$330,518,000
Forward EPS
$-0.60
Max Pain — expiry 2027-01-15
max pain strike: $7.00 · spot: $13.51 · call oi: 9,502 · put oi: 384
Expected Move to 2027-01-15:
±$2.88
(21.28%) —
implied range
$10.63 –
$16.38
· ATM straddle on $14.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $1.94B | $33.01 | — |
| SEPN | Septerna, Inc. | $1.90B | $40.02 | — |
| VERA | Vera Therapeutics, Inc. | $1.89B | $26.20 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.88B | $27.75 | — |
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
News headlines (Yahoo Finance, 1h cache)
Does Wider Losses Change The Bull Case For Trevi Therapeutics Stock (TRVI)?
2026-11-10 20:09 · Yahoo
Trevi Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-10 13:30 · Yahoo
Trevi Therapeutics Inc (TRVI) Q3 2026 Earnings Call Highlights: Strong Cash Position, FDA ...
2026-11-10 07:09 · Yahoo
Trevi Therapeutics (TRVI) Q3 2026 Earnings Call Transcript
2026-11-10 06:47 · Yahoo
What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call
2026-11-09 23:14 · Yahoo
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-09 21:05 · Yahoo
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
2026-11-02 21:05 · Yahoo
Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book Value
2026-11-01 16:05 · Yahoo
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
2026-10-27 11:30 · Yahoo
Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?
2026-10-13 22:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.